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Background: The choice of surgical treatment for patients with Multiple Endocrine
Neoplasia type 1 (MEN1)-related primary hyperparathyroidism (PHPT) remains
controversial and it has not been specifically addressed in young patients.
Methods: This is a retrospective case series study. The study includes the surgical data
and the follow-up of 38 patients younger than 30 years of age, all diagnosed with MEN1,
collected and followed-up between 1991 and 2017 at the Regional Referral Center for
Inherited Endocrine Tumors of the Tuscany Region, and operated by parathyroidectomy.
Genetic and/or clinical MEN1 diagnosis was made before surgery in all patients. Subtotal
(9/38 patients) or total parathyroidectomy with auto-transplantation (28/38 patients) were
performed in all patients but one, in whom a single mediastinal adenoma was excised
from the aorto-pulmonary window. All patients but one, who was operated in 2017, had
a post-operatory follow-up of at least 12 months.
Results: Total parathyroidectomy (TPTX), with auto-transplantation, was the most
frequently adopted operation both as primary (20/38 patients) and secondary (8/38
patients) surgery, followed by subtotal parathyroidectomy (SPTX; 9/38 patients) and
limited parathyroidectomy (1/38 patient). At follow-up, lasting a mean of 11.8± 6.6 years
(range 0–23 years), no persistent PHPT was observed. PHPT recurred in 4/28 TPTX
(14%) and in 2/9 SPTX (22%). Permanent hypoparathyroidism showed no statistically
significant difference between the procedures (2/9 in SPTX and 5/28 in TPTX).
Conclusions: Data from this retrospective study showed the efficacy of TPTX for the
treatment of MEN1-PHPT, also in adolescent and young patients, showing, in our series,
no risk of PHPT permanence and a longer disease-free period and, subsequently, the
possibility to postpone re-intervention with respect to both limited PTX and SPTX. The
risk of permanent hypoparathyroidism in TPTX was comparable to STPX, and could be
mitigated over the years.
Keywords: multiple endocrine neoplasia type 1, primary hyperparathyroidism, parathyroid adenoma,
parathyroidectomy, young MEN1 patients
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INTRODUCTION
Primary hyperparathyroidism (PHPT) is the most common
and, usually, the earliest endocrine manifestation in Multiple
Endocrine Neoplasia type 1 (MEN1).
Both timing and type of surgery for MEN1-PHPT remain
controversial and rarely investigated by clinical randomized
trials. The most common choice is to operate symptomatic
cases (1). Parathyroid surgery not only grants the restoration of
normal serum parathyroid hormone (PTH) and calcium level,
but is also beneficial for the control of gastrin oversecretion
in MEN1 patients with a concomitant active gastrinoma (2).
Post-surgical restoration of normal calcemia demonstrated also
to promote short-term partial recovery of trabecular bone
mineral density at lumbar spine and femoral neck and to
strongly reduce the manifestation of nephrolithiasis and related
secondary kidney co-morbidities (3). Two of the most frequently
performed parathyroid surgical interventions in MEN1-PHPT
are: subtotal parathyroidectomy (SPTX), consisting in the
removal of three/three and a half glands, leaving in site the
entire, or a remnant similar-size piece, of the fourth non-enlarged
parathyroid gland; or total parathyroidectomy (TPTX) with
autologous graft of pieces of the apparently non adenomatous
parathyroid tissue in the non-dominant forearm (4). Trans-
cervical thymectomy is usually performed, during both these
procedures, to prevent thymic carcinoid and remove possible
ectopic parathyroid glands (5). However, some reports have
shown that limited excision of the affected parathyroid glands
could obtain the same result in correcting the hypercalcemia,
with a lower risk of persistent hypoparathyroidism (6–8).
The PHPT age of onset is usually during the third decade of
life; mean age of surgery is after 35 years of age for most of the
patients. However, early onset of PHPT can occur in children
and adolescents affected by MEN1 syndrome. Until now, the
type and the result of surgery employed in young patients for
the treatment of MEN1-PHPT have rarely been addressed in
large series of patients, except for a recent study by Goudet et al.
which revised a wide population of patients under the age of
21 (9). However, it is not yet clear if young patients have an
aggressive type of PHPT responsible for persistence or recurrence
of PHPT more frequently than older patients, and if the same
MEN1 guidelines applied to adults must be followed also for
young individuals (1). In this paper, we describe our surgical
experience with MEN1-PHPT patients younger than 30 years,
collected, clinically managed, and followed-up over the past 26
years, at the Regional Referral Center for Inherited Endocrine
Tumors of the Tuscany Region.
PATIENTS AND METHODS
Patients
This study was approved by the Review Board of the “Area
Vasta Centro, Regione Toscana” at the “Azienda Ospedaliera-
Universitaria Careggi,” Florence (Rif. CEAVCOSS 16.234), and all
patients (or legal tutors for individuals <18 years) gave informed
consent for data collection and analysis. Each patient was
identified by a study-specific anonymous identification number.
Patients with MEN1-PHPT who underwent a first
parathyroidectomy (PTX) before 30 years of age were collected,
clinically managed, and followed-up over the past 26 years at the
Regional Referral Center for Inherited Endocrine Tumors of the
Tuscany Region, and operated on by our surgical team between
1991 and 2017.
This is a retrospective case series. Patients were included in
the MEN1 database if they had a genetically proved MEN1, or
if they showed at least two of the three main manifestations of
MEN1 syndrome (i.e., PHPT, anterior pituitary adenoma, and
neuroendocrine tumors of the gastro-entero-pancreatic tract),
or developed one of the three main manifestations and had a
first-degree relative affected by MEN1 (2).
Sanger’s sequencing analysis of theMEN1 gene was performed
in all these subjects. Index cases were analyzed by sequencing of
the coding region (exons 2–10) and splicing sites of the gene,
while relatives of a mutated MEN1 patient were screened only
for the family-specificMEN1mutation. One sequencing-negative
patient was further screened by Multiplex Ligation-dependent
Probe Amplification (MLPA). Two sequencing-negative brothers
were screened by microsatellite-based family linkage at the 11q13
locus.
The majority of these patients were surgically treated by the
same surgeon (F.T.). Nine patients, previously operated in other
institutions, were submitted to neck re-exploration (secondary
parathyroid operation performed within a mean of 6 years from
the first surgery) after a previous limited PTX (7/9 patients),
which had consisted, in all but one of the cases, in the removal of a
single parathyroid gland, or a previous SPTX (2/9 patients). Four
were re-operated because of a neck persistent PHPT (persistence
of post-operatory elevated serum level of PTH) and five because
of a neck recurrent PHPT (recurrence of elevated serum level of
PTH months/years after parathyroid surgery).
In all patients, evaluation of the parathyroid glands was
performed by echo-color Doppler ultrasonography and cervical
and mediastinal scintigraphy by Tc-99m sestamibi. Additional
localizing examinations were performed selectively, as clinically
indicated, by magnetic resonance imaging (MRI), merged images
of technetium-99-m-MIBI SPECT/CT (single photon emission
computed tomography/computed tomography), 4D computed
tomography (4DCT) and Casanova test (a specific intact PTH-
dosing test, able to discriminate between the graft-bearing arm
and the neck as the site of the hyperparathyroidism recurrence).
Surgical Interventions
The standard surgical approach was by a cervical incision,
performing a bilateral exploration with isolation of inferior
laryngeal nerves and an attempt to identify all the parathyroid
glands. Two procedures are employed: the SPTX, leaving an
entire or a part of one parathyroid gland in the neck (the one
appearing not to be enlarged), and marking the site with a
metallic clip; or TPTX, removing all the parathyroid glands and
grafting fragments of the parathyroid gland appearing as non-
adenomatous. From 8 to 10 pieces (about 1 mm3 in volume) of
fresh parathyroid tissue were transplanted into pockets between
the muscular fibers of the brachio-radial muscle of the non-
dominant forearm, at the end of neck operation. In some
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patients, the subcutaneous adipose tissue of the volar forearm
was preferred as site of transplant. The time from the tissue
collection to the transplant was 58 ± 13min; parathyroid tissue
was preserved in sterile lactated Ringer at +4◦C. Efforts were
made to recognize or confirm, on the basis of the preoperative
localization study, ectopic and/or supernumerary glands, and
remove them. The thymus was also removed in all patients by
trans cervical approach.
Intra-operative PTH Monitoring
Intra-operative PTHmonitoring was accessible to all parathyroid
operated patients at the “Azienda Ospedaliera-Universitaria
Careggi” from 1990. In all our patients, the quick intra-operative
determination of intact PTH was determined at the induction
of anesthesia, and subsequently just before and at 10–20min
after excision of each gland. The last sampling was performed
at the end of surgery, 30–60min after excision of the last
parathyroid gland, in order to have the data before performing
the parathyroid implant (10).
Follow-Up
All patients but one, who was operated in 2017, had a post-
operatory follow-up of at least 12 months (mean 11.8 ±
6.6 years; range 0–23 years). The serum calcium and PTH
concentrations were monitored the first post-operative day and
every month after discharge. Persistent PHPT was defined if
the following parameters were present during the initial 6
months after the operation: (1) reproducible hypercalcemia
and elevated or inappropriate PTH levels; (2) absence of
normocalcemic intervals. Recurrent PHPT was defined when
calcemia and PTH levels increased 6 months or more after
post-operative normocalcemia. Permanent hypoparathyroidism
was defined when hypocalcemia (serum ionized or albumin-
corrected calcium levels below 1.10 or 2.20 mmol/L, respectively)
persisted beyond the first postoperative 6 months, requiring
calcium and vitamin D substitution therapy (11).
Statistical Analysis
Clinical and surgical data, age at diagnosis and at surgical
intervention, post-operatory outcomes and complications were
all analyzed by descriptive statistics; data are presented as
nominal categories, percentages, or mean ± standard deviation
(SD). Differences in the mean age of MEN1 patients at surgery
between the different types of surgery were analyzed by the
Student’s t-test; p < 0.05 was considered as the statistical
significance. Differences in recurrence rate and permanent
hypoparathyroidism rate between TPTX and SPTX were
analyzed by Chi-squared test with Yates’ correction; p < 0.05 was
considered as the statistical significance.
RESULTS
Thirty-eight patients (26 females and 12 males) developed
MEN1-associated PHPT before the age of 30 years (mean age of
PHPT clinical diagnosis 22.7± 5.3 years; range 13–30 years) and
underwent PTX at our referral center as primary (29/38 patients)
or secondary (9/38 patients) operation.
Genetic screening identified 33/38MEN1mutated individuals
by Sanger’s sequencing, one patient as carrier of a large intragenic
deletion spanning more than one exon of the gene by MLPA and
two brothers as carriers of a family-specific MEN1-predisposing
haplotype by family linkage analysis of 11q13 locus.
Our series included 11/38 MEN1 single cases (9/11 with an
identified MEN1 gene mutation, and two without an identified
germline MEN1 mutation by Sanger sequencing, but clinically
diagnosed with MEN1) and 27/38 familial MEN1 cases from 18
different kindreds (25/27 with an identifiedMEN1 gene mutation
and 2 without an identified germline MEN1 mutation by Sanger
sequencing but with a MEN1 clinical diagnosis, a family history
of MEN1 and a positive 11q13 family linkage analysis). Sixteen
patients were referred to our endocrine referral center as affected
index cases (11 MEN1 single cases and 5 MEN1 familial case).
The mean age of MEN1 patients at surgery was 23.2 ± 4.9
years (range 13–30 years). No statistically significant difference
regarding the age of the patients between the different types of
surgery was found. Thirty patients (73.2%) underwent PTX the
same year as PHPT clinical diagnosis (0-year gap). The mean gap
between PHPT clinical diagnosis and surgery was 0.8± 1.9 years.
TPTX was the most commonly employed operation (28/38
patients), followed by SPTX (9/38 patients) and limited PTX
(1/38 patient). TPTXwas performed as first intervention in 20/28
patients, as a secondary intervention after a previous limited PTX
in 6/28 patients, and after a previous SPTX in 2/28 patients.
SPTX was performed as a first operation in 8/9 patients and as
a secondary intervention 1/9 patient, after a limited PTX, during
which two parathyroid glands were removed.
Main characteristics and post-surgical outcomes of SPTX and
TPTX are reported in Table 1.
The only patient referred for a limited PTX was a 17-
year-old boy affected by a single adenoma of a mediastinal
ectopic parathyroid gland sited in the aorto-pulmonary window,
removed through a left thoracotomy. The patient showed no sign
of PHPT persistence or recurrence, and neck parathyroid glands
were not affected at the time of this study, 3 years after surgery.
No damage of recurrent laryngeal nerve, PHPT persistence, or
complications were observed during the first surgery in all our 37
patients, both for SPTX and TPTX.
At the follow-up, recurrence of PHPT was observed in
2/9 SPTX (22.2%) and in 4/28 TPTX (14.3%). No statistically
significant difference in recurrence rate was observed between
SPTX and TPTX (p= 1.00). The two recurrences after SPTXwere
both re-operated at the neck, performing a secondary TPTX.
Three of four recurrences (75%) after the TPTX occurred at
the forearm transplant site. Two of these patients were referred
for a second intervention to remove part of the transplant
in the forearm; the third was treated with Cinacalcet. The
fourth recurrence after TPTX occurred in the neck, because
of an adenoma in a fifth supernumerary parathyroid gland,
which had not been identified and removed during the first
TPTX. The second TPTX consisted of a cervical re-operation
to remove a neck-located adenoma; this intervention resulted
to be particularly difficult, causing a temporary paralysis of the
recurrent nerve and rupturing the adjacent carotid artery, which
was repaired with a graft.
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TABLE 1 | Clinical characteristics, type of surgery, and post-surgical outcomes of
37 young MEN1 patients who underwent SPTX or TPTX.
SPTX (≥3 glands
removed)
TPTX (all
parathyroids
removed)
n. patients 9 28
Previous PTX (n. patients) 1 8
Gender (M/F ratio) 4/5 7/21
Age at surgery (mean ± standard
deviation)
Range
Primary SPTX:
24.7 ± 3.3
19–30 years
Secondary SPTX: 21
years
Primary TPTX:
23.1 ± 5.3
13–30 years
Secondary TPTX:
31.7 ± 5.4
24–42 years
PHPT post-operative persistence 0 0
PHPT post-operative recurrence 2 (22.2%) 4 (14.3%)
Time to recurrence (years) 7.0 ± 2.0
5–9 years
10.7 ± 0.8
10–12 years
Site of recurrence (n.) Neck (2) Neck (1)
Forearm (3)
n. PTX re-interventions 2 (22.2%) 3 (10.7%)*
Post-surgical permanent
hypoparathyroidism
2 (22.2%) 5 (17.9%)
Years of follow-up after surgery
(mean ± SD)
Range
First SPTX: 7.8 ± 7.7
0–22 years
13.1 ± 5.7
1–23 years
PTX, parathyroidectomy; SPTX, subtotal parathyroidectomy; TPTX, total
parathyroidectomy; PHPT, primary hyperparathyroidism; SD, standard deviation.
*One of four patients presenting recurrent PHPT has normal calcemia and has not
undergone parathyroid re-intervention at the time of this study (she was treated with
Cinacalcet).
Post-operatory temporary hypoparathyroidism was observed
in all the 28 TPTX patients and in 2/9 SPTX. It regressed
spontaneously after 3–4 months in 23/28 (82.1%) of TPTX-
operated patients; conversely, 2/9 SPTX (22.2%) and 5/28 TPTX
(17.9%) manifested permanent hypoparathyroidism. Permanent
hypoparathyroidism rate showed no statistically significant
difference between SPTX and TPTX (p= 0.84).
No association has been found between type and localization
of MEN1 mutations and PHPT clinical presentation and/or
response to surgery, or between patients with a positive or a
negative genetic test.
DISCUSSION
MEN1 endocrine tumors are caused by germline inactivating
mutations of the tumor suppressor gene MEN1 (12). According
to the “two hits” mechanism of action for tumor suppressor
genes, the second wild type copy of the gene is lost or
inactivated at the somatic level in tumors. This process
happen independently in the four parathyroids, and it explains
why the growth of the parathyroid glands is differently and
asynchronously affected. At least one parathyroid gland is,
usually, foundmacroscopically “normal” in 10–20% of theMEN1
patients, at the time of surgical exploration for the treatment
of PHPT (13, 14). Furthermore, between 11.9 and 16% of the
parathyroid glands removed and histologically examined are
normal in MEN1 patients at the time of the PTX (7, 14).
Interestingly, no correlation has been found between the volume
of the parathyroid glands and the age of the patients with MEN1-
related PHPT (13).
The surgical treatment of PHPT in MEN1 patients is
usually a compromise between leaving non adenomatous
parathyroid tissue sufficient enough to avoid a permanent
hypoparathyroidism and removing all the tumor glands to
prevent persistence or prompt recurrence of PHPT. This goal
can be better achieved either with SPTX or TPTX. In both these
procedures, the approximate volume of non tumoral parathyroid
gland must be preserved or implanted (11, 15). However,
the asynchronous and asymmetrical growth of the parathyroid
glands, the presence of at least one normal parathyroid gland in
some patients, the fact that any operation leaving parathyroid
tissue implies a risk for recurrent disease, and the frequency of
ectopic and/or supernumerary gland higher than expected and
often located in non-conventional sites or embedded within the
cervical fatty tissue make surgical treatment of MEN1-PHPT
extremely challenging.
Also parathyroid fragments, re-implanted after a TPTX,
cause recurrence; our experience showed them as the most
common site of PHPT recurrence in TPTX. The modalities of
transplant are empirical: the number of parathyroid fragments
to be implanted is a controversial point. Most surgeons insert
at least 20 fragments (16–18), but it is not clear if they are
completely vital at the moment of the implant. Our approach
utilizes fresh parathyroid tissue, rigorously maintained at +4◦C
between explant and re-implantation, to reduce to a minimum
the ischemic time. According to our experience, 10 fragments of
about 1 mm3 in volume, are enough to guarantee that they take
root and maintain an adequate parathyroid function. However,
research on the ideal number of fragments and the modality of
implant should be implemented to clarify this technical point.
The revision of several surgical experiences on wide series
of patients, published in recent years, showed clearly that
persistent PHPT is more frequent after SPTX than after TPTX;
meanwhile, recurrent PHPT has a similar frequency for the two
types of surgery (19). However, the rate of PHPT recurrence is
strongly dependent on the length of follow-up, as recurrences
happen earlier after SPTX than TPTX (15, 19, 20). These
data are confirmed by a meta-analysis (21) and by the only
randomized clinical trial performed until now (18). All these
studies also highlighted how both transitory and permanent
hypoparathyroidism is more frequent after TPTX than SPTX.
However, hypoparathyroidism may improve progressively with
time, as demonstrated in patients with the longest follow-up in
absence of a replacement therapy (15).
Very little information about surgical treatment of PHPT
in young patients affected by MEN1 syndrome is available in
literature; surgical experience of MEN1-PHPT has been globally
referred to all the patients. The Group d’étude des tumeurs
endocrines has recently revised a large population of patients
aging <21 years (9). Out of 160 MEN1 patients, PHPT was
diagnosed in 122 (75%). Only 37 of them (30.3%) were operated,
either for clinical symptoms or hypercalcemia. Operation before
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10 years of age was very rare in this experience (only one patient).
Half of these patients were operated with SPTX, 26% with single
parathyroid gland excision, and 21% with excision of 2 or 2.5
parathyroid glands. At follow-up (the patients were followed
until 21 years of age), which was completed for only 67%, most
of the patients were normocalcemic and only 4 (11%) were
hypocalcemic. Persistent or recurrent PHPTwas observed in 22%
and reoperation was performed in 5%.
It is difficult to establish only from these data if young patients
are more prone to persistence or recurrence of PHPT than
older patients. In particular, a comparison between SPTX and
TPTX was not specifically performed in young patients. The
results from our study and from our surgical experience show
that TPTX is effective and indicated also in young patients,
and it is better to perform an aggressive surgery than a limited
PTX. MEN1 patients are at risk of having an inadequate type
of surgery, especially when familial PHPT is not suspected and
genetic testing has not been performed before surgery. In our
surgical experience, we have had the advantage of operating most
of the patients already knowing that they were carriers of a form
of PHPT due to MEN1 gene mutation. In all but one patient,
TPTX or SPTXwere performed. Nine of these interventions were
requested as second intervention, after a period of between 3 and
14 years, for 5 PHPT persistence and 4 relapses, secondary to a
previous limited PTX or a SPTX, not performed in our center.
On the basis of these findings, the hypothesis that at time of the
diagnosis of PHPT in young MEN1 patients only one or two
parathyroid glands are affected and there is a long time period
before the other parathyroid glands become hyperfunctioning is
not persuasive. Recently, the NIH experience regarding different
surgical approaches to treat PHPT in MEN1 syndrome was
referred byNilubol et al. (22). Patients were studied and followed-
up using a strict protocol. Sixteen patients were submitted to
a limited PTX (<2 glands): 11 of them had a persistence of
PHPT and 3 a recurrence of PHPT. The authors concluded that
a limited PTX, even if guided by preoperative localizing studies,
is associated with a significantly higher rate of persistent PHPT
compared to excision of over 3.5 parathyroid glands. The main
cause of the failure of a limited PTX is the inadequacy of the
preoperative localizing studies, missing enlarged controlateral
parathyroid glands in 86% of the patients. However, other
authors have obtained positive results with limited interventions,
such as the unilateral clearance (excision of the parathyroid
glands and thymus from only one cervical side) (8, 23) or selective
parathyroidectomy (7, 24, 25). Most of the patients operated by
limited PTX are older, and there is too little follow-up time for
the results achieved to be reliable (22).
The reason for early onset of PHPT and greater recurrence
after surgery in some patients has not yet been clarified. At
this time, it remains controversial whether there is a genotype-
phenotype correlation for the severity of PHPT. The Dutch
MEN1 study found a lower risk of persistent or recurrent PHPT
after less than SPTX in presence of nonsense or frameshift
mutations in exons 2, 9, and 10 (26). Mutation in exon 3 of the
MEN1 gene has been found to be linked to risk of recurrence (15).
Our study did not confirm these findings.
From our experience, it has been confirmed that re-
intervention at the cervical level can be at risk for serious
complications, and it must therefore be avoided as much as
possible, performing the most efficacious type of surgery as first
operation.
In conclusion, our data showed the efficacy of TPTX for the
treatment ofMEN1-PHPT, also in adolescent and young patients,
showing, in our series, no risk of PHPT permanence and a longer
disease-free period and, subsequently, the possibility to postpone
re-intervention with respect to both limited PTX and SPTX. The
risk of permanent hypoparathyroidism in TPTX was comparable
to STPX, and could be mitigated over the years.
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